These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 8133465)

  • 1. Comparison of four basic models of indirect pharmacodynamic responses.
    Dayneka NL; Garg V; Jusko WJ
    J Pharmacokinet Biopharm; 1993 Aug; 21(4):457-78. PubMed ID: 8133465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers.
    Derendorf H; Möllmann H; Krieg M; Tunn S; Möllmann C; Barth J; Röthig HJ
    Pharm Res; 1991 Feb; 8(2):263-8. PubMed ID: 2023879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone.
    Daley-Yates PT; Gregory AJ; Brooks CD
    Br J Clin Pharmacol; 1997 Jun; 43(6):593-601. PubMed ID: 9205819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dosage regimen in controlling indirect pharmacodynamic responses.
    Gobburu JV; Jusko WJ
    Adv Drug Deliv Rev; 2001 Mar; 46(1-3):45-57. PubMed ID: 11259832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects.
    Kong AN; Ludwig EA; Slaughter RL; DiStefano PM; DeMasi J; Middleton E; Jusko WJ
    Clin Pharmacol Ther; 1989 Dec; 46(6):616-28. PubMed ID: 2689044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone.
    Möllmann H; Hochhaus G; Rohatagi S; Barth J; Derendorf H
    Pharm Res; 1995 Jul; 12(7):1096-100. PubMed ID: 7494809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of four basic models of indirect pharmacodynamic responses.
    Sharma A; Jusko WJ
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):611-35. PubMed ID: 9300353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm.
    Fisher LE; Ludwig EA; Wald JA; Sloan RR; Middleton E; Jusko WJ
    Clin Pharmacol Ther; 1992 Jun; 51(6):677-88. PubMed ID: 1535301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients.
    Tornatore KM; Reed K; Walshe JJ; Venuto RC
    Pharmacotherapy; 1994; 14(1):111-8. PubMed ID: 8159595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models.
    Lin S; Chien YW
    J Pharm Pharmacol; 2002 Jun; 54(6):791-800. PubMed ID: 12078995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers.
    Booker BM; Magee MH; Blum RA; Lates CD; Jusko WJ
    Clin Pharmacol Ther; 2002 Oct; 72(4):370-82. PubMed ID: 12386639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2001 Feb; 28(1):57-78. PubMed ID: 11253614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass.
    Hornik CP; Gonzalez D; Dumond J; Wu H; Graham EM; Hill KD; Cohen-Wolkowiez M
    CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):913-922. PubMed ID: 31646767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of high-dose methylprednisolone in children.
    Ito S; Kusunoki Y; Oka T; Ito Y; Okuno A; Yoshioka H
    Dev Pharmacol Ther; 1992; 19(2-3):99-105. PubMed ID: 1340442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids.
    Derendorf H; Hochhaus G; Möllmann H; Barth J; Krieg M; Tunn S; Möllmann C
    J Clin Pharmacol; 1993 Feb; 33(2):115-23. PubMed ID: 8440759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.
    Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M
    Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats.
    Fang J; DuBois DC; He Y; Almon RR; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2011 Jun; 38(3):293-316. PubMed ID: 21394487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver.
    Sun YN; DuBois DC; Almon RR; Pyszczynski NA; Jusko WJ
    J Pharmacokinet Biopharm; 1998 Dec; 26(6):619-48. PubMed ID: 10485078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids.
    Jusko WJ
    Toxicology; 1995 Sep; 102(1-2):189-96. PubMed ID: 7482553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.